The latest business, scientific & regulatory news from the pharmaceutical and biotechnology industries.
September 8, 2010
September 08, 2010.
|
August 25, 2010
By:
George Koroneos
Results from a new study reveal that patients taking Takeda's diabetes treatment Actos have the same rate and kind of side effects as GSK's embattled Avandia. Is this a good sign?
|
August 18, 2010
By:
George Koroneos
In a huge blow to Eli Lilly's Alzheimer's pipeline, the drug giant was forced to end two clinical trials due to the fact that the treatment was actually making patients' memory recall worse.
|
August 11, 2010
By:
George Koroneos
Head-and-neck cancer treatment trial flops in Phase 3 trials causing Amgen stock to drop. The first-line therapy failed first and secondary goals compared with chemotherapy alone.
|
August 4, 2010
By:
George Koroneos
In the wake of FDA's refusal to approve the lead drug in NicOx's pipeline, the French firm has decided to close its US headquarters.
|
August 2, 2010
By:
George Koroneos
Former Idun Pharma team buys back company from Pfizer.
|
July 28, 2010
By:
Reid Paul, Pharm Rep Magazine
Bonuses for reps at GlaxoSmithKline will soon be based on customer feedback and adherence to company policy, not sales targets. The move promises to transform sales & marketing, but the company offered few details about how the plan will be implemented.
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
